Dr. Bhojani and Dr. Chew discuss sepsis after ureteroscopy
“Sepsis is real, and it's around 5%. I was surprised too, but this is what the actual data shows, and we should be aware of it,” says Ben H. Chew, MD, MSc.
In this video, Naeem Bhojani, MD, FRCSC, and Ben H. Chew, MD, MSc, discuss the background and findings of the studies, “Identifying predictors of sepsis post-ureteroscopy in a US-based population: results from the Endourological Society TOWER Collaborative,” and “What is the cost of sepsis after ureteroscopy? Results from the Endourological Society TOWER Collaborative.” Bhojani is an associate professor of urology, clinical research scholar FRQ-S, and endourologist at the Centre Hospitalier de l'Université de Montréal, Quebec. Chew is an associate professor of urologic sciences at the University of British Columbia, Vancouver.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
